TILRAY BRANDS INC (TLRY.CA) Stock Fundamental Analysis

TSX:TLRY • US88688T2096

10.8 CAD

+0.39 (+3.75%)

Last: Feb 19, 2026, 07:00 PM

Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to TLRY. TLRY was compared to 33 industry peers in the Pharmaceuticals industry. TLRY has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, TLRY is valued expensive at the moment.

Quickly go to:

1. Profitability 2. Health 3. Growth 4. Valuation 5. Dividend

1. Profitability

1.1 Basic Checks

In the past year TLRY has reported negative net income.
TLRY had a negative operating cash flow in the past year.
In the past 5 years TLRY always reported negative net income.
TLRY had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -100.42%, TLRY is doing worse than 84.85% of the companies in the same industry.
TLRY's Return On Equity of -133.40% is on the low side compared to the rest of the industry. TLRY is outperformed by 75.76% of its industry peers.

		Industry Rank	Sector Rank
ROA	-100.42%
ROE	-133.4%
ROIC	N/A

ROA(3y)-48.32%

ROA(5y)-36.47%

ROE(3y)-65.2%

ROE(5y)-55.79%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TLRY's Gross Margin of 28.02% is in line compared to the rest of the industry. TLRY outperforms 42.42% of its industry peers.
TLRY's Gross Margin has improved in the last couple of years.
TLRY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	28.02%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y16.36%

GM growth 5YN/A

More info and screens

ROA ROE ROIC Operating and Profit Margin Show most profitable peers

2. Health

2.1 Basic Checks

TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLRY has been increased compared to 1 year ago.
Compared to 5 years ago, TLRY has more shares outstanding
TLRY has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -1.63, we must say that TLRY is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.63, TLRY is not doing good in the industry: 63.64% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.18 indicates that TLRY is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.18, TLRY is in the better half of the industry, outperforming 60.61% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.18
Debt/FCF	N/A
Altman-Z	-1.63

ROIC/WACCN/A

WACC8.31%

2.3 Liquidity

TLRY has a Current Ratio of 2.81. This indicates that TLRY is financially healthy and has no problem in meeting its short term obligations.
TLRY's Current ratio of 2.81 is fine compared to the rest of the industry. TLRY outperforms 69.70% of its industry peers.
TLRY has a Quick Ratio of 1.72. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
TLRY has a Quick ratio of 1.72. This is in the better half of the industry: TLRY outperforms 78.79% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.81
Quick Ratio	1.72

More info and screens

WACC Debt/Equity How to determine the health of a company Altman-Z score Show peers with great health

3. Growth

3.1 Past

The earnings per share for TLRY have decreased strongly by -379.00% in the last year.
Looking at the last year, TLRY shows a small growth in Revenue. The Revenue has grown by 0.98% in the last year.
The Revenue has been growing by 37.52% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-379%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%59%

Revenue 1Y (TTM)0.98%

Revenue growth 3Y9.34%

Revenue growth 5Y37.52%

Sales Q2Q%3.11%

3.2 Future

TLRY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.42% yearly.
The Revenue is expected to grow by 4.15% on average over the next years.

EPS Next Y96.56%

EPS Next 2Y40.59%

EPS Next 3Y25.77%

EPS Next 5Y15.42%

Revenue Next Year3.75%

Revenue Next 2Y4.25%

Revenue Next 3Y4.03%

Revenue Next 5Y4.15%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

TLRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLRY. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as TLRY.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	22.17

4.3 Compensation for Growth

TLRY's earnings are expected to grow with 25.77% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y40.59%

EPS Next 3Y25.77%

More info and screens

Price/Earnings Price/FCF FCF per share EV/EBITDA PEG RATIO Show best valued peers

5. Dividend

5.1 Amount

No dividends for TLRY!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks Show peers with best dividend

TILRAY BRANDS INC

TSX:TLRY (2/19/2026, 7:00:00 PM)

10.8

+0.39 (+3.75%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)01-08 2026-01-08/amc

Earnings (Next)04-06 2026-04-06/bmo

Inst Owners11.21%

Inst Owner ChangeN/A

Ins Owners0.35%

Ins Owner ChangeN/A

Market Cap1.26B

Revenue(TTM)837.32M

Net Income(TTM)-2.11B

Analysts70.59

Price Target17.33 (60.46%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-0.49%

Min EPS beat(2)-100.98%

Max EPS beat(2)100%

EPS beat(4)1

Avg EPS beat(4)-1374.81%

Min EPS beat(4)-5362.97%

Max EPS beat(4)100%

EPS beat(8)1

Avg EPS beat(8)-733.35%

EPS beat(12)2

Avg EPS beat(12)-748.47%

EPS beat(16)3

Avg EPS beat(16)-621.09%

Revenue beat(2)2

Avg Revenue beat(2)0.75%

Min Revenue beat(2)0.41%

Max Revenue beat(2)1.09%

Revenue beat(4)2

Avg Revenue beat(4)-4.75%

Min Revenue beat(4)-13.28%

Max Revenue beat(4)1.09%

Revenue beat(8)2

Avg Revenue beat(8)-5.24%

Revenue beat(12)3

Avg Revenue beat(12)-2.69%

Revenue beat(16)3

Avg Revenue beat(16)-3.19%

PT rev (1m)-26.56%

PT rev (3m)553.4%

EPS NQ rev (1m)16%

EPS NQ rev (3m)-833.33%

EPS NY rev (1m)-2.3%

EPS NY rev (3m)-1134.12%

Revenue NQ rev (1m)-0.31%

Revenue NQ rev (3m)0.07%

Revenue NY rev (1m)-0.17%

Revenue NY rev (3m)0.06%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.1
P/FCF	N/A
P/OCF	N/A
P/B	0.58
P/tB	1.14
EV/EBITDA	22.17

EPS(TTM)-19.69

EYN/A

EPS(NY)-0.49

Fwd EYN/A

FCF(TTM)-0.8

FCFYN/A

OCF(TTM)-0.33

OCFYN/A

SpS9.85

BVpS18.58

TBVpS9.47

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-100.42%
ROE	-133.4%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	28.02%
FCFM	N/A

ROA(3y)-48.32%

ROA(5y)-36.47%

ROE(3y)-65.2%

ROE(5y)-55.79%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y16.36%

GM growth 5YN/A

F-Score3

Asset Turnover0.4

Health

		Industry Rank	Sector Rank
Debt/Equity	0.18
Debt/FCF	N/A
Debt/EBITDA	7.07
Cap/Depr	40.31%
Cap/Sales	4.77%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.81
Quick Ratio	1.72
Altman-Z	-1.63

F-Score3

WACC8.31%

ROIC/WACCN/A

Cap/Depr(3y)21.23%

Cap/Depr(5y)65.01%

Cap/Sales(3y)3.68%

Cap/Sales(5y)7.53%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-379%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%59%

EPS Next Y96.56%

EPS Next 2Y40.59%

EPS Next 3Y25.77%

EPS Next 5Y15.42%

Revenue 1Y (TTM)0.98%

Revenue growth 3Y9.34%

Revenue growth 5Y37.52%

Sales Q2Q%3.11%

Revenue Next Year3.75%

Revenue Next 2Y4.25%

Revenue Next 3Y4.03%

Revenue Next 5Y4.15%

EBIT growth 1Y41.7%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year109.23%

EBIT Next 3Y28.5%

EBIT Next 5Y17.22%

FCF growth 1Y-53.53%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-33.64%

OCF growth 3YN/A

OCF growth 5YN/A

TILRAY BRANDS INC / TLRY.CA FAQ

Can you provide the ChartMill fundamental rating for TILRAY BRANDS INC?

ChartMill assigns a fundamental rating of 2 / 10 to TLRY.CA.

What is the valuation status for TLRY stock?

ChartMill assigns a valuation rating of 1 / 10 to TILRAY BRANDS INC (TLRY.CA). This can be considered as Overvalued.

How profitable is TILRAY BRANDS INC (TLRY.CA) stock?

TILRAY BRANDS INC (TLRY.CA) has a profitability rating of 1 / 10.